awmsg logo



atomoxetine (Strattera®)


Reference No. 1361

Publication date:
27/02/2014


Last review date:
01/12/2016

Appraisal information

atomoxetine (Strattera®) 10 mg capsule
atomoxetine (Strattera®) 18 mg capsule
atomoxetine (Strattera®) 25 mg capsule
atomoxetine (Strattera®) 40 mg capsule
atomoxetine (Strattera®) 60 mg capsule
atomoxetine (Strattera®) 80 mg capsule
atomoxetine (Strattera®) 100 mg capsule


Company: Eli Lilly & Co Ltd
BNF category: Central nervous system
NMG meeting date: 27/11/2013
AWMSG meeting date: 15/01/2014
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0214
Ministerial ratification: 26/02/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Atomoxetine (Strattera®) is recommended for use within NHS Wales for the initiation of treatment in adults with attention deficit hyperactivity disorder (ADHD). Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria or the guidelines in International Classification of Mental and Behavioural Disorders (ICD). In adults, the presence of symptoms of ADHD that were pre-existing in childhood should be confirmed. Third-party corroboration is desirable and atomoxetine should not be initiated when the verification of childhood ADHD symptoms is uncertain. Diagnosis cannot be made solely on the presence of one or more symptoms of ADHD. Based on clinical judgment, patients should have ADHD of at least moderate severity as indicated by at least moderate functional impairment in two or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download